Zobrazeno 1 - 10
of 3 822
pro vyhledávání: '"SGLT2 Inhibitor"'
Autor:
Sven O. Göpel, Damilola Adingupu, Jue Wang, Elizaveta Semenova, Margareta Behrendt, Rasmus Jansson-Löfmark, Christine Ahlström, Ann-Cathrine Jönsson-Rylander, V. Sashi Gopaul, Russell Esterline, Li-Ming Gan, Rui-Ping Xiao
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-15 (2024)
Abstract Background SGLT2 inhibitors, a T2DM medication to lower blood glucose, markedly improve cardiovascular outcomes but the underlying mechanism(s) are not fully understood. SGLT2i’s produce a unique metabolic pattern by lowering blood glucose
Externí odkaz:
https://doaj.org/article/e4b485641d78496b9714711ae24f8c10
Autor:
Jaejin An, John J. Sim, Matt M. Zhou, Hui Zhou, Soon Kyu Choi, Jeffrey W. Brettler, Angeline L. Ong‐Su, Kristi Reynolds
Publikováno v:
The Journal of Clinical Hypertension, Vol 26, Iss 11, Pp 1318-1321 (2024)
ABSTRACT Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) have demonstrated a blood pressure (BP) reduction benefit despite other indications for use. We evaluated BP changes and antihypertensive medication use pre‐ and post‐SGLT2i initiati
Externí odkaz:
https://doaj.org/article/5d48affa22d145f6bf244528bf7d3ae9
Autor:
Xuehong Li, Qiong Li, Xinying Jiang, Shicong Song, Wei Zou, Qinglan Yang, Sirui Liu, Shuangqin Chen, Cheng Wang
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-23 (2024)
Abstract Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have changed the therapeutic landscape for diabetic kidney disease (DKD) patients, but their underlying mechanisms are complicated and not fully understood. Mitochondria-associated
Externí odkaz:
https://doaj.org/article/5edb44d28528469a95948bfe6666e4bf
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract This study was aimed to evaluate whether the dose–response relationship of the sodium glucose co-transporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)—canagliflozin, dapagliflozin, empagliflozin, ipraglifloz
Externí odkaz:
https://doaj.org/article/c8f7851be87649e49f1166c1f49d57a8
Autor:
Yushi Hirota, Yasumasa Kakei, Junta Imai, Hideki Katagiri, Ken Ebihara, Jun Wada, Junichi Suzuki, Tatsuhiko Urakami, Takashi Omori, Wataru Ogawa
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 9, Pp 1211-1219 (2024)
ABSTRACT Aims/Introduction Insulin resistance syndrome and lipoatrophic diabetes are rare conditions characterized by the development of treatment‐refractory diabetes with severe insulin resistance. We recently conducted a 24 week, multicenter, sin
Externí odkaz:
https://doaj.org/article/d60e2f3c3183423c9437d2a067c99250
Autor:
Jiaqi Mei, Yi Li, Liyan Niu, Ruikai Liang, Mingyue Tang, Qi Cai, Jingdong Xu, Deju Zhang, Xiaoping Yin, Xiao Liu, Yunfeng Shen, Jianping Liu, Minxuan Xu, Panpan Xia, Jitao Ling, Yuting Wu, Jianqi Liang, Jing Zhang, Peng Yu
Publikováno v:
Translational Neurodegeneration, Vol 13, Iss 1, Pp 1-16 (2024)
Abstract The rising prevalence of diabetes mellitus has casted a spotlight on one of its significant sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for diabetes management, are increasingly stu
Externí odkaz:
https://doaj.org/article/cb6395b5728842fd94ce981f3e3ddf45
Autor:
Jaclyn Carberry, Mark C. Petrie, Matthew M.Y. Lee, Katriona Brooksbank, Ross T. Campbell, Richard Good, Pardeep S. Jhund, Peter Kellman, Ninian N. Lang, Kenneth Mangion, Patrick B. Mark, Alex McConnachie, John J.V. McMurray, Barbara Meyer, Vanessa Orchard, Aadil Shaukat, Stuart Watkins, Paul Welsh, Naveed Sattar, Colin Berry, Kieran F. Docherty
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 2001-2012 (2024)
Abstract Aims Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are at risk of progressive adverse cardiac remodelling that can lead to the development of heart failure and death. The earl
Externí odkaz:
https://doaj.org/article/2392cabc2be74029819f96fb1ade1e0f
Autor:
Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, John G.F. Cleland, Ninian N. Lang, Mark C. Petrie, Michele Robertson, Ian Ford
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 1875-1879 (2024)
Abstract Aims To explore the potential interaction between use of SGLT2 inhibitors and the increase in haemoglobin in patients randomized to intravenous iron or the control group in the IRONMAN (Effectiveness of Intravenous Iron Treatment versus Stan
Externí odkaz:
https://doaj.org/article/7b8685721c094d3f8713fa148d206e05
Publikováno v:
Molecular Medicine, Vol 30, Iss 1, Pp 1-14 (2024)
Abstract Background Patients with type 2 diabetes often face early tubular injury, necessitating effective treatment strategies. This study aimed to evaluate the impact of the SGLT2 inhibitor empagliflozin on early tubular injury biomarkers in type 2
Externí odkaz:
https://doaj.org/article/cc533448d7aa46769f24c41e9b4e368e
Autor:
Qi Gao, Yingying Jiang, Zhenqiang Song, Huizhu Ren, Yan Kong, Cong Wang, Miaoyan Zheng, Chunyan Shan, Yanhui Yang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Lipid peroxidation and mitochondrial damage impair insulin sensitivity in skeletal muscle. Sirtuin-1 (SIRT1) protects mitochondria and activates under energy restriction. Dapagliflozin (Dapa) is an antihyperglycaemic agent that belongs to th
Externí odkaz:
https://doaj.org/article/f864967b1e704871a9f4f74eab9f24c3